Literature DB >> 31707040

Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.

Narasimha Kumar Karanam1, Lianghao Ding1, Asaithamby Aroumougame1, Michael D Story2.   

Abstract

Tumor treating fields (TTFields) is a noninvasive physical modality of cancer therapy that applies low-intensity, intermediate frequency, and alternating electric fields to a tumor. Interference with mitosis was the first mechanism describing the effects of TTFields on cancer cells; however, TTFields was shown to not only reduce the rejoining of radiation-induced DNA double-strand breaks (DSBs), but to also induce DNA DSBs. The mechanism(s) by which TTFields generates DNA DSBs is related to the generation of replication stress including reduced expression of the DNA replication complex genes MCM6 and MCM10 and the Fanconi's Anemia pathway genes. When markers of DNA replication stress as a result of TTFields exposure were examined, newly replicated DNA length was reduced with TTFields exposure time and there was increased R-loop formation. Furthermore, as cells were exposed to TTFields a conditional vulnerability environment developed which rendered cells more susceptible to DNA damaging agents or agents that interfere with DNA repair or replication fork maintenance. The effect of TTFields exposure with concomitant exposure to cisplatin or PARP inhibition, the combination of TTFields plus concomitant PARP inhibition followed by radiation, or radiation alone at the end of a TTFields exposure were all synergistic. Finally, gene expression analysis of 47 key mitosis regulator genes suggested that TTFields-induced mitotic aberrations and DNA damage/replication stress events, although intimately linked to one another, are likely initiated independently of one another. This suggests that enhanced replication stress and reduced DNA repair capacity are also major mechanisms of TTFields effects, effects for which there are therapeutic implications.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31707040     DOI: 10.1016/j.trsl.2019.10.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  15 in total

1.  Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo.

Authors:  Shiri Davidi; Sara Jacobovitch; Anna Shteingauz; Antonia Martinez-Conde; Ori Braten; Catherine Tempel-Brami; Einav Zeevi; Roni Frechtel-Gerzi; Hila Ene; Eyal Dor-On; Tali Voloshin; Itai Tzchori; Adi Haber; Moshe Giladi; Adrian Kinzel; Uri Weinberg; Yoram Palti
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

Review 2.  Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids.

Authors:  Eva Petermann; Li Lan; Lee Zou
Journal:  Nat Rev Mol Cell Biol       Date:  2022-04-22       Impact factor: 113.915

Review 3.  An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19.

Authors:  Ahmad Reza Farmani; Forough Mahdavinezhad; Carolina Scagnolari; Mahsa Kouhestani; Sadegh Mohammadi; Jafar Ai; Mohammad Hasan Shoormeij; Nima Rezaei
Journal:  Drug Deliv Transl Res       Date:  2021-09-20       Impact factor: 4.617

Review 4.  Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers.

Authors:  Travis H Jones; Jonathan W Song; Laith Abushahin
Journal:  Transl Oncol       Date:  2021-11-27       Impact factor: 4.243

5.  Targeting Accuracy Considerations for Simultaneous Tumor Treating Fields Antimitotic Therapy During Robotic Hypofractionated Radiation Therapy.

Authors:  Sharmi Biswas; Irina Kapitanova; Sabrina Divekar; Jimm Grimm; Ian J Butterwick; Daniel Garren; Lawrence R Kleinberg; Kristin J Redmond; Michel Lacroix; Anand Mahadevan; Kenneth M Forster
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

6.  Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.

Authors:  Dongjiang Chen; Son B Le; Tarun E Hutchinson; Anda-Alexandra Calinescu; Mathew Sebastian; Dan Jin; Tianyi Liu; Ashley Ghiaseddin; Maryam Rahman; David D Tran
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

Review 7.  Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.

Authors:  Mario E Lacouture; Milan J Anadkat; Matthew T Ballo; Fabio Iwamoto; Suriya A Jeyapalan; Renato V La Rocca; Margaret Schwartz; Jennifer N Serventi; Martin Glas
Journal:  Front Oncol       Date:  2020-07-28       Impact factor: 6.244

Review 8.  DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.

Authors:  Ola Rominiyi; Spencer J Collis
Journal:  Mol Oncol       Date:  2021-06-11       Impact factor: 6.603

Review 9.  Tumor Treating Fields in the Management of Patients with Malignant Gliomas.

Authors:  Ashley P Ghiaseddin; David Shin; Kaitlyn Melnick; David D Tran
Journal:  Curr Treat Options Oncol       Date:  2020-07-30

Review 10.  Electrotherapies for Glioblastoma.

Authors:  Elise P W Jenkins; Alina Finch; Magda Gerigk; Iasonas F Triantis; Colin Watts; George G Malliaras
Journal:  Adv Sci (Weinh)       Date:  2021-07-22       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.